Analysts expect that Obalon Therptcs (NASDAQ:OBLN) will report earnings of ($0.43) per share for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for Obalon Therptcs’ earnings. The lowest EPS estimate is ($0.47) and the highest is ($0.39). The firm is scheduled to announce its next earnings results on Wednesday, August 9th.
On average, analysts expect that Obalon Therptcs will report full-year earnings of ($1.82) per share for the current financial year, with EPS estimates ranging from ($1.86) to ($1.77). For the next fiscal year, analysts forecast that the business will report earnings of ($1.64) per share, with EPS estimates ranging from ($1.65) to ($1.64). Zacks Investment Research’s EPS calculations are an average based on a survey of analysts that follow Obalon Therptcs.
Obalon Therptcs (NASDAQ:OBLN) last announced its quarterly earnings data on Wednesday, May 10th. The company reported ($0.47) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by $0.14. The company had revenue of $1.47 million for the quarter, compared to the consensus estimate of $1.60 million.
A number of equities research analysts have recently commented on OBLN shares. BTIG Research reiterated a “buy” rating and set a $20.00 price target on shares of Obalon Therptcs in a report on Sunday, March 19th. Canaccord Genuity reiterated a “buy” rating on shares of Obalon Therptcs in a report on Monday, April 17th. Zacks Investment Research downgraded shares of Obalon Therptcs from a “buy” rating to a “hold” rating in a report on Wednesday, April 26th. ValuEngine upgraded shares of Obalon Therptcs from a “strong sell” rating to a “sell” rating in a report on Friday, June 2nd. Finally, Northland Securities assumed coverage on shares of Obalon Therptcs in a report on Wednesday, June 21st. They set an “under perform” rating and a $6.00 price target for the company. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company. Obalon Therptcs has a consensus rating of “Hold” and a consensus price target of $14.20.
Large investors have recently added to or reduced their stakes in the company. Moisand Fitzgerald Tamayo LLC acquired a new position in shares of Obalon Therptcs during the first quarter worth $358,000. Emerald Advisers Inc. PA acquired a new position in shares of Obalon Therptcs during the first quarter worth $108,000. UBS Group AG boosted its position in shares of Obalon Therptcs by 90.8% in the first quarter. UBS Group AG now owns 11,856 shares of the company’s stock worth $127,000 after buying an additional 5,641 shares during the period. Bank of New York Mellon Corp acquired a new position in shares of Obalon Therptcs during the first quarter worth $168,000. Finally, Keybank National Association OH acquired a new position in shares of Obalon Therptcs during the fourth quarter worth $155,000. 61.63% of the stock is currently owned by institutional investors and hedge funds.
Obalon Therptcs (NASDAQ:OBLN) traded down 0.11% during trading on Friday, reaching $9.05. 15,258 shares of the company’s stock traded hands. Obalon Therptcs has a 1-year low of $8.27 and a 1-year high of $15.88. The firm has a 50 day moving average of $10.30 and a 200 day moving average of $10.06. The firm’s market capitalization is $151.97 million.
Obalon Therptcs Company Profile
Obalon Therapeutics, Inc is a United States-based commercial-stage medical device company focused on developing and commercializing medical devices to treat obese and overweight people by facilitating weight loss. The Company’s product, Obalon balloon system, is a swallowable, gas-filled intragastric balloon designed to provide weight loss in obese patients.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2285825/zacks-analysts-expect-obalon-therptcs-nasdaqobln-to-announce-0-43-earnings-per-share.html
Receive News & Ratings for Obalon Therptcs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Obalon Therptcs and related companies with MarketBeat.com's FREE daily email newsletter.